Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Up – Time to Buy?

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)’s share price gapped up prior to trading on Thursday. The stock had previously closed at $9.41, but opened at $10.0250. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $9.6150, with a volume of 3,694 shares traded.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on SGIOY. Jefferies Financial Group raised Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 14th. Zacks Research upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 15th. Three analysts have rated the stock with a Strong Buy rating. According to data from MarketBeat.com, Shionogi & Co., Ltd. Unsponsored ADR has an average rating of “Strong Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Stock Performance

The firm’s fifty day moving average is $9.10 and its 200 day moving average is $9.22. The firm has a market capitalization of $16.38 billion, a price-to-earnings ratio of 9.62, a PEG ratio of 3.37 and a beta of 0.08. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.14 and a quick ratio of 1.00.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last released its quarterly earnings data on Monday, August 3rd. The company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.18. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 46.67% and a return on equity of 16.13%. The firm had revenue of $1.04 billion for the quarter, compared to analyst estimates of $970.69 million. On average, analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 EPS for the current fiscal year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. is a Japanese pharmaceutical company headquartered in Osaka, Japan. Founded in 1878, the company researches, develops, manufactures and markets prescription medicines, with a longstanding focus on infectious diseases and specialty therapies.

Its products and development programs have included Xofluza (baloxavir marboxil), an oral treatment for influenza; Fetroja (cefiderocol), an antibiotic for certain difficult-to-treat Gram-negative bacterial infections; and medicines for central nervous system disorders, pain and other therapeutic areas.